Versão BETA

Acesso livre
Acesso livre

Clínica Médica

Dr. Fauci afirma que os riscos trazidos pela variante Delta acentuam a importância das vacinas.

18 Jun, 2021 | 10:38h

Dr. Fauci Says The Risks From The Delta Variant Underscore The Importance Of Vaccines – NPR


Opinião | Causalidade ou confusão: por que os grupos controle são fundamentais para caracterizar a “long COVID” – “Muitos dos sintomas autorrelatados, como cefaleias intermitentes ou cansaço, são inespecíficos e prevalentes na população geral.”

18 Jun, 2021 | 10:37h

Causation or confounding: why controls are critical for characterizing long COVID – Nature


Estudo mostra que a taxa de reinfecção por COVID-19 é inferior a 1% em pacientes que tiveram doença grave.

18 Jun, 2021 | 10:35h

COVID-19 reinfection rate less than 1 percent for those with severe illness, study finds – University of Missouri-Columbia

Estudo original: Re-infection with SARS-CoV-2 in Patients Undergoing Serial Laboratory Testing – Clinical Infectious Diseases


Recomendações da ECMM/ISHAM para o manejo clínico da mucormicose associada à COVID-19 em países de baixa e média rendas.

18 Jun, 2021 | 10:34h

ECMM/ISHAM recommendations for clinical management of COVID -19 associated mucormycosis in low- and middle-income countries – Mycosis


Estudo de coorte | Desfechos relacionados a deglutição e voz em pacientes hospitalizados com COVID-19.

18 Jun, 2021 | 10:33h

Swallowing and Voice Outcomes in Patients Hospitalized With COVID-19: An Observational Cohort Study – Archives of Physical Medicine and Rehabilitation

Estudo relacionado: Characterization of dysphagia and laryngeal findings in COVID-19 patients treated in the ICU—An observational clinical study – PLOS One


Outra metanálise suporta a interrupção de aspirina 1 a 3 meses após intervenção coronariana percutânea e a continuidade do tratamento em monoterapia com inibidor de P2Y12.

18 Jun, 2021 | 10:30h

P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials – The BMJ

Relacionado: M-A: After an acute coronary syndrome treated with coronary stenting, dual antiplatelet therapy (DAPT) for 1 to 3 months followed by P2Y12 inhibitor monotherapy is associated with improved outcomes compared with traditional DAPT for 12 months.


M-A | Tratamentos agudos para enxaqueca episódica em adultos.

18 Jun, 2021 | 10:28h

Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis – JAMA (gratuito por tempo limitado)

Editorial: Acute Treatment for Migraine: Contemporary Treatments and Future Directions (gratuito por tempo limitado)

 

Comentário no Twitter (fio – clique para saber mais)

 


Estudo randomizado | Efeitos do eptinezumabe intravenoso vs. placebo sobre a cefaleia e outros sintomas quando administrado no início de uma crise de enxaqueca.

18 Jun, 2021 | 10:27h

Effects of Intraven.ous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial – JAMA (gratuito por tempo limitado)

Editorial: Acute Treatment for Migraine: Contemporary Treatments and Future Directions (gratuito por tempo limitado)

Comentário: Migraine Prevention Drug Eptinezumab Shows Efficacy in Treating Acute Attacks – Physician’s Weekly

 

Comentário no Twitter (fio – clique para saber mais)

 


Estudo randomizado | Tofacitinibe reduziu o risco de morte ou insuficiência respiratória em pacientes hospitalizados com pneumonia por Covid-19.

17 Jun, 2021 | 11:06h

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia – New England Journal of Medicine

Comunicado de imprensa: Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia

 

Comentário no Twitter:

 


[Preprint] Estudo RECOVERY descobre que a combinação de anticorpo monoclonal Regeneron reduz as mortes de pacientes hospitalizados com COVID que não desenvolveram sua própria resposta imunológica.

17 Jun, 2021 | 11:04h

Comunicado de imprensa: RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

Estudo original (preprint): Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv

Comentários: Monoclonal antibodies cut risk of dying from COVID-19—but only in some patients – Science E Antibody combo cuts COVID deaths by 20% in very ill seronegative patients – CIDRAP E Regeneron antibody saves lives in some hospitalized Covid patients, study finds – STAT E Expert reaction to press release from the RECOVERY trial reporting that Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response – Science Media Centre

 

Comentário no Twitter

 


Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.